IMA203

IMA203 is a TCR-T cell therapy developed by Immatics US. Its target is PRAME (the sponsor names PRAME). The sponsor states: An autologous, genetically engineered T-cell receptor (TCR)-T cell therapy directed against PRAME-expressing tumour cells, given as a one-time infusion followed by adjunctive low-dose IL-2 therapy for up to 10 days. ClinicalTrials.gov describes the intervention as: one-time administration of IMA203, and adjunctive therapy with low dose interleukin (IL)-2 for up to 10 days, starting approximately 24 h after IMA203 infusion, optional bridging therapy. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06743126 (SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma), in melanoma. The largest, NCT06743126, plans to enrol 360 participants with primary completion expected 2028-01. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.